Australia markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
52.47+1.82 (+3.59%)
At close: 04:03PM EDT
52.95 +0.48 (+0.91%)
Pre-market: 08:30AM EDT
Full screen
Loading interactive chart…
  • Financial Times

    Pfizer to seek US emergency approval of Covid vaccine for under 5s

    Pfizer has said it will seek emergency authorisation in the US for its Covid-19 vaccine for children under the age of five after interim results from its clinical trial showed the jab is safe and highly effective. The US drugmaker said on Monday that three doses of its children’s jab — each about a tenth of the size of an adult dose — produced a strong immune response with a favourable safety profile similar to a placebo in the age group. An authorisation would open up the last large market for the Covid vaccine, potentially paving the way for a longer-term revenue stream if it became part of the childhood immunisation schedule.

  • Business Wire

    Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

    NEW YORK & MAINZ, Germany, May 23, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo.

  • Simply Wall St.

    Is There An Opportunity With Pfizer Inc.'s (NYSE:PFE) 50% Undervaluation?

    Does the May share price for Pfizer Inc. ( NYSE:PFE ) reflect what it's really worth? Today, we will estimate the...